Supplementary Figure S1 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS^G12C-Mutated Metastatic Colorectal Cancer

Supplementary Figure S1. Changes from baseline in sum of target lesion diameters over time for patients continuing treatment after progression, either with adagrasib plus cetuximab (n = 38), adagrasib only (n = 10), or cetuximab only (n = 1). Only patients with available post-progression scans are included in the plot (n = 33 for adagrasib plus cetuximab; n = 1 for adagrasib only).